BioCentury | Sep 17, 2020
Deals

Mirati and Boehringer partner to test KRAS-KRAS combo

...2019 deal to run a combination study with the pharma’s SHP-2 inhibitor TNO115.  TARGETSKRAS (K-Ras) SHP-2 (SHPTP2; PTPN11...
...Inc. Amgen Inc. Boehringer Ingelheim GmbH KRAS proto-oncogene, GTPase (KRAS) (K-Ras) Son of sevenless homolog 1 (SOS1) Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11) Cancer Non-small...
BioCentury | Aug 11, 2020
Emerging Company Profile

Through LianBio, Perceptive forms bridge for Western pipeline into Asia

...30-50Funds raised: UndisclosedInvestors: Perceptive AdvisorsCEO: Bing LiPatents: UndisclosedTARGETSFGFR – Fibroblast growth factor receptorSHP-2 (SHPTP2; PTPN11) – Src homology protein tyrosine phosphatase 2 Sandi...
...Src homology protein tyrosine phosphatase 2 Sandi Wong mavacamten (SAR439152, myk-461) infigratinib (BGJ398) Perceptive Advisors BridgeBio Pharma Inc. MyoKardia Inc. Cardiac myosin Fibroblast growth factor (FGF) receptor (FGFR) Src homology protein tyrosine phosphatase 2 (SHP-2...
...SAR439152, myk-461) infigratinib (BGJ398) Perceptive Advisors BridgeBio Pharma Inc. MyoKardia Inc. Cardiac myosin Fibroblast growth factor (FGF) receptor (FGFR) Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11) Cardiovascular Cardiomyopathy LianBio BBP-398 chs2020...
BioCentury | Jul 16, 2020
Finance

Relay’s IPO among the year’s largest for a biotech as others wait in wings

...Targets FGFR2 (KGFR; CD332) - Fibroblast growth factor (FGF) receptor 2 SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul...
BioCentury | Jun 26, 2020
Regulation

Data Bytes: CHMP’s June opinions

A recommendation by EMA’s CHMP suggests remdesivir from Gilead Sciences Inc. (NASDAQ:GILD) could soon gain a speedy conditional approval to treat COVID-19. The committee announced the decision this week along with a basket of other...
BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BioCentury | Jun 2, 2020
Product Development

Sanofi makes case for why its first cancer drug in a decade can take on Darzalex

...and modalities, several of which will read out over the next 18 months including a SHP-2...
...cell death 1 PD-L1 (B7-H1; CD274) - Programmed cell death 1 ligand 1 SHP-2 (SHPTP2; PTPN11...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

...SIX:NOVN) and Boehringer Ingelheim GmbH will highlight new stabs at the pathway via inhibitors of SHP-2...
...Poly(ADP-ribose) polymerase PARP-7 - Poly(ADP-ribose) polymerase-7 PBRM1 (PB1) - Polybromo 1 SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2...
BioCentury | Feb 14, 2020
Finance

You say you want a Revolution? Oncology company is latest to post big gain after IPO

...SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos, Associate Editor Revolution Medicines Inc. Ras Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Src homology protein tyrosine phosphatase 2...
...SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos, Associate Editor Revolution Medicines Inc. Ras Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Src homology protein tyrosine phosphatase 2 (SHP-2...
...PTPN11) - Src homology protein tyrosine phosphatase 2 Paul Bonanos, Associate Editor Revolution Medicines Inc. Ras Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1) Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2...
BioCentury | Feb 1, 2020
Preclinical News

Preclinical Roundup: CureVac gets CEPI funding for 2019 coronavirus; plus blockade of CD47-SIRPA for atherosclerosis, Stanford and IBM-CDHI

CureVac gets CEPI funding for 2019 coronavirus The Coalition for Epidemic Preparedness Innovations and CureVac AG are extending a February 2019 collaboration to include a vaccine against the 2019-nCoV acute respiratory disease. The company will...
BioCentury | Jan 23, 2020
Financial News

Jan. 22 Financial Quick Takes: Genmab-J&J, Adaptimmune, Revolution, PDC*line

...is in Phase I/II testing for non-small cell lung cancer. Targets: SHP-2 (SHPTP2; PTPN11) - Src homology protein tyrosine phosphatase 2...
...of rapamycin Hongjiang Li, Staff Writer Revolution Medicines Inc. Genmab A/S Johnson & Johnson Adaptimmune Therapeutics plc PDC*line Pharma Src homology protein tyrosine phosphatase 2 (SHP-2) (SHPTP2) (PTPN11) Mammalian...
Items per page:
1 - 10 of 2479